Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Insight Molecular Diagnostics Inc. (IMDX)

iMDx Q2 net loss widens to $11.3 million; FDA issues request for more information

Negative Impact 4 of 5 earnings Written later

Insight Molecular Diagnostics reported second-quarter 2026 revenue of $239,000, down from $518,000 a year earlier, and a net loss of $11.3 million, or $0.31 per share, versus $9.7 million, or $0.30 per share, in the prior-year quarter. The company also disclosed that the FDA issued an Additional Information Request on its GraftAssureDx submission, which requires a complete response within 180 days; management calls the request routine.

Key points

  • Q2 2026 revenue was $239,000 versus $518,000 in Q2 2025; gross profit was $157,000.
  • Q2 2026 net loss was $11.3 million ($0.31 per share) versus $9.7 million ($0.30 per share) in Q2 2025; non-GAAP net loss was $8.3 million ($0.23 per share).
  • The FDA issued an Additional Information Request on GraftAssureDx, with a complete response due within 180 days; the company expects one more FDA meeting before the fourth quarter of 2026.
  • Cash, cash equivalents and restricted cash was $18.7 million at June 30, 2026; Q2 free cash outflow was approximately $10 million.

The filing

CompanyInsight Molecular Diagnostics Inc. (IMDX)
Form8-K, current report
Filed with the SECAug 10, 2026, 4:10 PM ET
Accession number0001493152-26-036863

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.